Chargement en cours...
Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center
Andexanet alfa is approved for the reversal of factor Xa inhibitors in patients with major bleeding events. We aimed to review the incidence of effective hemostasis with andexanet alfa in a real-world environment. This retrospective cohort included patients hospitalized for a major bleed that result...
Enregistré dans:
| Publié dans: | Clin Appl Thromb Hemost |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SAGE Publications
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7019392/ https://ncbi.nlm.nih.gov/pubmed/31876159 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1076029619896619 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|